Intraoperative Quantification of Residual IDH1-mutant Tumor Cells Via Ultra-Rapid Droplet Digital PCR
This study is testing a new, super-fast lab technique to help surgeons identify leftover brain tumor cells during an operation. By detecting these specific tumor cells in real-time, the surgical team can be more precise about removing as much of the tumor as possible while you are still in the operating room.
You may be eligible if you are 18 or older and are scheduled for brain surgery at NYU Langone Health to treat a glioma (a type of brain tumor) that has a specific genetic feature called an IDH mutation.
During your scheduled surgery, the medical team will take small tissue samples to analyze using a special device that looks for remaining tumor cells. If the test shows that tumor cells are still present, your surgeon will use that information to decide if they can remove more of the tumor right then and there.
The study takes place at NYU Langone Health in New York City. It is currently not yet recruiting participants, meaning it is still in the preparation stages.
- 1The goal is to help surgeons remove as much of the tumor as possible during a single surgery.
- 2Participation does not require extra surgeries or procedures beyond what you were already scheduled for.
- 3Safety rules mean that people with certain active infections, like hepatitis C, cannot participate in this specific study.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.